Su-11248 Sugen

Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39.

Abstract

SUGEN is developing SU-11248, an orally active inhibitor of platelet-derived growth factor tyrosine kinase (TK) and other TK signaling pathways, as a potential anticancer agent. By October 2003, phase III trials for gastrointestinal stromal tumors and renal cell carcinoma were underway.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Drugs, Investigational / chemistry
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use*
  • Humans
  • Indoles / chemistry
  • Indoles / pharmacology
  • Indoles / therapeutic use*
  • Pyrroles / chemistry
  • Pyrroles / pharmacology
  • Pyrroles / therapeutic use*
  • Sunitinib

Substances

  • Antineoplastic Agents
  • Drugs, Investigational
  • Indoles
  • Pyrroles
  • Sunitinib